DISC MEDICINE INC (IRON)

What DISC MEDICINE INC does

Disc Medicine is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases. The company's pipeline targets fundamental biological pathways associated with red blood cell formation and function, specifically heme biosynthesis and iron homeostasis. Current clinical programs include bitopertin for erythropoietic porphyrias, DISC-0974 for anemia in myelofibrosis and inflammatory bowel disease, and DISC-3405 for polycythemia vera and sickle cell disease.

Fundamentals

• Price$78.94 as of 2026-07-09 close
• Market cap$3.0B as of 2026-07-10
• 1-year return+51.1% as of 2026-07-09 close
• ROE-37.0% as of 2026-07-10
• Debt / equity0.04 as of 2026-07-10
• Beta0.97 as of 2026-07-10

Ask why IRON looks like this →

Key risks (from latest filing)

["Clinical-stage company with no approved products or revenue; bitopertin received a complete response letter from FDA in February 2026 regarding the surrogate endpoint uncertainty linking PPIX reduction to clinical benefit in porphyria patients","Significant ongoing losses and reliance on additional capital funding; company has not yet progressed any product candidates through Phase 3 completion","Development approach focused on novel pathways with little clinical experience; regulatory approval uncertain as some programs use new endpoints and methodologies that FDA may not accept as clinically meaningful predictors"]

See IRON's biggest risks from its latest 10-Q →

Competitors & peers

• Vertex Pharmaceuticals (VERX) – for sickle cell disease programs
• CRISPR Therapeutics (CRSP) – for sickle cell disease and blood disorder therapies
• Forma Therapeutics – for hematologic disease programs
• Ionis Pharmaceuticals (IONS) – for blood disorder antisense therapies

Not quite? Describe exactly what you want →